Shao Gaohai, Zhou Changlong, Ma Kunlong, Zhao Wang, Feng Guibo, Xiong Qijiang, Yang Ling, Yang Zhao
1Department of orthopedics, Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160 China.
2Department of Neurology, Yongchuan Hospital, Chongqing Medical University, Chongqing, 402160 China.
J Inflamm (Lond). 2020 Jan 31;17:3. doi: 10.1186/s12950-020-0239-6. eCollection 2020.
INTRODUCTION: Glioma is an aggressive common cancer with high mortality worldwide. Up to date, the effective medical therapeutical strategy is limited. Numerous previous studies have indicated that glioma-expressed antigen 2 (GLEA2) might be an attractive prognostic glioma biomarker. METHODS: In this experiment, dendritic cells (DCs) transduced with GLEA2 recombinant adenovirus were utilized to generate cytotoxic lymphocytes (CTLs) in vitro. Additionally, trimera mice were immunized with the transduced DCs to generate CTLs in vivo. RESULTS: The data demonstrated that GLEA2 transduced DCs could effectively generate specific CTL response against glioma without lysing autologous lymphocytes. Moreover, GLEA2 transduced DCs significantly attenuated the tumor growth and prolonged the life span of tumor bearing mice. CONCLUSIONS: These findings suggested that DCs transduced with GLEA2 recombinant adenovirus could generate effective CTL mediated anti-tumor response, and might represent insight in glioma therapy.
World J Gastroenterol. 2008-1-28
Exp Mol Pathol. 2014-10
World J Gastroenterol. 2003-7
Toxicol Res. 2024-11-20
Rep Pract Oncol Radiother. 2019
Cancer Res. 2018-10-15
Proc Jpn Acad Ser B Phys Biol Sci. 2018